Clioquinol down-regulates mutant huntingtin expression in vitro and mitigates pathology in a Huntington's disease mouse model
Open accessThe DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Abstract
In investigating the role of metal ions in the pathogenesis of Huntington's disease, we examined the effects of clioquinol, a metal-binding compound currently in clinical trials for Alzheimer's disease treatment, on mutant huntingtin-expressing cells. We found that PC12 cells expressing polyglutamine-expanded huntingtin exon 1 accumulated less mutant protein and showed decreased cell death when treated with clioquinol. This effect was polyglutamine-length-specific and did not alter mRNA levels or protein degradation rates. Clioquinol treatment of transgenic Huntington's mice ( R6 / 2 ) improved behavioral and pathologic phenotypes, including decreased huntingtin aggregate accumulation, decreased striatal atrophy, improved rotarod performance, reduction of weight loss, normalization of blood glucose and insulin levels, and extension of lifespan. Our results suggest that clioquinol is a candidate therapy for Huntington's disease and other polyglutamine-expansion diseases.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The iron chelator clioquinol is also protective (Nguyen et al. 2005).”
Citations
Cites
Neurodegenerative diseases and oxidative stress
Barnham, K. J., Masters, C. L., & Bush, A. I. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1330 · Cited by 3,683
Mangiarini, L., Sathasivam, K., Seller, M., Cozens, B., Harper, A., Hetherington, C., Lawton, M., Trottier, Y., Lehrach, H., Davies, S. W., et al. (1996) · Cell · doi:10.1016/s0092-8674(00)81369-0 · Cited by 3,073
Davies, S. W., Turmaine, M., Cozens, B. A., DiFiglia, M., Sharp, A. H., Ross, C. A., Scherzinger, E., Wanker, E. E., Mangiarini, L., & Bates, G. P. (1997) · Cell · doi:10.1016/s0092-8674(00)80513-9 · Cited by 2,181
Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death
Arrasate, M., Mitra, S., Schweitzer, E. S., Segal, M. R., & Finkbeiner, S. (2004) · Nature · doi:10.1038/nature02998 · Cited by 1,979
Saudou, F., Finkbeiner, S., Devys, D., & Greenberg, M. E. (1998) · Cell · doi:10.1016/s0092-8674(00)81782-1 · Cited by 1,595
Analytical profiles of drug substances
(1975) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.2600640947 · Cited by 1,491
Cherny, R. A., Atwood, C. S., Xilinas, M. E., Gray, D. N., Jones, W. D., McLean, C. A., Barnham, K. J., Volitakis, I., Fraser, F. W., Kim, Y.-S., et al. (2001) · Neuron · doi:10.1016/s0896-6273(01)00317-8 · Cited by 1,447
Gauthier, L. R., Charrin, B. C., Borrell-Pagès, M., Dompierre, J. P., Rangone, H., Cordelières, F. P., De Mey, J., MacDonald, M. E., Leßmann, V., Humbert, S., et al. (2004) · Cell · doi:10.1016/j.cell.2004.06.018 · Cited by 1,178
Loss of Huntingtin-Mediated BDNF Gene Transcription in Huntington's Disease
Zuccato, C., Ciammola, A., Rigamonti, D., Leavitt, B. R., Goffredo, D., Conti, L., MacDonald, M. E., Friedlander, R. M., Silani, V., Hayden, M. R., et al. (2001) · Science · doi:10.1126/science.1059581 · Cited by 1,123
Reversal of Neuropathology and Motor Dysfunction in a Conditional Model of Huntington's Disease
Yamamoto, A., Lucas, J. J., & Hen, R. (2000) · Cell · doi:10.1016/s0092-8674(00)80623-6 · Cited by 1,067
Research works printed but not linked: 3
- Perez, P., Flores, A., Santamaria, A., Rios, C. & Galvan-Arzate, S. (1996) Arch. Med. Res. 27, 449-452.8987176
- Maksimovic, I. D., Jovanovic, M. D., Colic, M., Mihajlovic, R., Micic, D., Selakovic, V., Ninkovic, M., Malicevic, Z., Rusic-Stojiljkovic, M. & Jovicic, A. (2001) Vojnosanit Pregl. 58, 237-242.11548547
- Ogata, M., Watanabe, S., Tateishi, J., Kuroda, S. & Otsuki, S. (1973) Lancet 1, 1248-1249.
Cited by
Items 101–195 of 195
Superoxide dismutase as a target of clioquinol-induced neurotoxicity
Kawamura, K., Kuroda, Y., Sogo, M., Fujimoto, M., Inui, T., & Mitsui, T. (2014) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2014.04.067 · Cited by 28
Simmons, D. A., Mills, B. D., Butler, R. R., Kuan, J., McHugh, T. L. M., Akers, C. S., Zhou, J., Syriani, W., Goubran, M., Zeineh, M., et al. (2021) · Neurotherapeutics · doi:10.1007/s13311-021-01023-8 · Cited by 31
Barrea, R. A., Chen, D., Irving, T. C., & Dou, Q. P. (2009) · Journal of Cellular Biochemistry · doi:10.1002/jcb.22231 · Cited by 29
“Recent studies show that CQ has the potential for the treatment of Alzheimer and Huntington diseases [Ritchie et al., 2004; Nguyen et al., 2005].”
ResultSweet and Sour - Oxidative and Carbonyl Stress in Neurological Disorders
Harris, R. A., & Amor, S. (2011) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152711794488656 · Cited by 31
Katsuyama, M., Iwata, K., Ibi, M., Matsuno, K., Matsumoto, M., & Yabe‐Nishimura, C. (2012) · Toxicology · doi:10.1016/j.tox.2012.05.013 · Cited by 29
Filiz, G., Caragounis, A., Bica, L., Du, T., Masters, C. L., Crouch, P. J., & White, A. R. (2007) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2007.11.003 · Cited by 33
Wang, T., Zheng, W., Xu, H. J., Zhou, J., & Wang, Z. (2010) · PLoS ONE · doi:10.1371/journal.pone.0011888 · Cited by 31
“In addition, it is also confirmed that CQ has positive effects in animal models of Parkinson’s disease and Huntington’s disease [24,25].”
BackgroundAnodic behavior of clioquinol at a glassy carbon electrode
Ghalkhani, M., Fernandes, I. P. G., Oliveira, S. C. B., Shahrokhian, S., & Oliveira‐Brett, A. M. (2010) · Bioelectrochemistry · doi:10.1016/j.bioelechem.2010.10.001 · Cited by 29
“CQ has been used to ameliorate the neurotoxicity of 1-methyl 4-phenyl 1,2,3,6-tetrahydropyridine (MPTP) in an animal model of Parkinson's disease [11] and also inhibits aggregation of mutant huntingtin protein and mitigated disease pathology in a murine model of Huntington's disease [12].”
BackgroundPrice, K. A., Filiz, G., Caragounis, A., Du, T., Laughton, K. M., Masters, C. L., Sharples, R. A., Hill, A. F., Li, Q., Donnelly, P. S., et al. (2008) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2008.01.033 · Cited by 25
Synthesis, spectroscopic, thermal and biological aspect of mixed ligand copper(II) complexes
Kharadi, G. J., & Patel, K. D. (2009) · Journal of Thermal Analysis and Calorimetry · doi:10.1007/s10973-009-0038-z · Cited by 25
“Recent reports indicate that that CQ also mitigates Huntington’s disease neuropathological symptoms in a mouse model of this disorder [ 29 ]; CQ treatment decreased the accumulation of huntingtin aggregates, suggesting commonalities in the etiology of both neurological pathologies.”
BackgroundHerrero, E. J., Arancibia, V., & Rojas−Romo, C. (2014) · Journal of Electroanalytical Chemistry · doi:10.1016/j.jelechem.2014.06.039 · Cited by 31
Chen, W.-H., Wang, M., Yu, S., Su, L., Zhu, D., She, J.-Q., Cao, X., & Ruan, D.-Y. (2007) · Neuroscience · doi:10.1016/j.neuroscience.2007.04.042 · Cited by 25
Mitochondrial deficiency: a double-edged sword for aging and neurodegeneration
Troulinaki, K., & Bano, D. (2012) · Frontiers in Genetics · doi:10.3389/fgene.2012.00244 · Cited by 28
“Clioquinol is a metal chelator that has been extensively used as a neuroprotective drug in Alzheimer’s, Parkinson’s, and Huntington’s models or even as a drug in patients, where it reduces the accumulation or the expression of the toxic proteins (Cherny et al., 2001; Kaur et al., 2003; Nguyen et al., 2005).”
BackgroundGuo, J.-P., Pan, J., Xiong, L., Xia, W.-F., Cui, S., & Xiong, W. (2015) · PLoS ONE · doi:10.1371/journal.pone.0139395 · Cited by 29
“As CQ is known to be a moderate iron chelator [21], we wondered whether other iron chelators have a similar effect as CQ on OC genesis.”
BackgroundMicroglial senescence in neurodegeneration: Insights, implications, and therapeutic opportunities
Olajide, T. S., Oyerinde, T. O., Omotosho, O. I., Okeowo, O. M., Olajide, O. J., & Ijomone, O. M. (2024) · Neuroprotection/Neuroprotection (Chichester, England. Print) · doi:10.1002/nep3.56 · Cited by 26
“167,168 M30, a versatile iron chelator identi fi ed as 5 ‐ (N ‐ methyl ‐”
Iron is a specific cofactor for distinct oxidation- and aggregation-dependent Aβ toxicity mechanisms
Ott, S., Dziadulewicz, N., & Crowther, D. C. (2015) · Disease Models & Mechanisms · doi:10.1242/dmm.019042 · Cited by 24
“, 2013) models of HD there is good evidence that both copper and iron metabolism are disturbed and that chelator therapy may be beneficial (Nguyen et al., 2005).”
Joaquim, A. R., Pippi, B., de Cesare, M. A., Rocha, D. A., Boff, R., Staudt, K. J., Ruaro, T. C., Zimmer, A. R., de Araújo, B. V., Silveira, G. P., et al. (2018) · Chemical Biology & Drug Design · doi:10.1111/cbdd.13435 · Cited by 30
Pretsch, D., Rollinger, J. M., Schmid, A., Genov, M., Wöhrer, T., Krenn, L., Moloney, M. G., Kasture, A. S., Hummel, T., & Pretsch, A. (2020) · Scientific Reports · doi:10.1038/s41598-020-68561-7 · Cited by 28
Bajpai, A., Bharathi, V., & Patel, B. K. (2024) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2024.177187 · Cited by 23
El‐Megharbel, S. M., & Refat, M. S. E.-D. (2015) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2014.12.081 · Cited by 23
Summers, K. L., Dolgova, N. V., Gagnon, K. B., Sopasis, G. J., James, A. K., Lai, B. C. H., Sylvain, N. J., Harris, H. H., Nichol, H. K., George, G. N., et al. (2020) · Metallomics · doi:10.1039/d0mt00222d · Cited by 23
Choi, B. Y., Kim, I. Y., Kim, J. H., Kho, A. R., Lee, S. H., Lee, B. E., Sohn, M., Koh, J., & Suh, S. W. (2016) · Neurobiology of Disease · doi:10.1016/j.nbd.2016.06.018 · Cited by 22
A mitochondrial basis for Huntington’s disease: therapeutic prospects
Chakraborty, J., Rajamma, U., & Mohanakumar, K. P. (2013) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-013-1951-9 · Cited by 23
“Clioquinol Protective in PC 12 cells expressing mHtt and R6/2, improves cell viability, behavior and striatal atrophy [145] No report”
BackgroundTeil, M., Doudnikoff, É., Thiolat, M.-L., Bohic, S., Bézard, E., & Dehay, B. (2022) · Molecular Neurobiology · doi:10.1007/s12035-022-02974-5 · Cited by 21
Evaluation of tetrathiomolybdate in the R6/2 model of Huntington disease
Tallaksen‐Greene, S. J., Janiszewska, A., Benton, K., Hou, G., Dick, R., Brewer, G. J., & Albin, R. L. (2009) · Neuroscience Letters · doi:10.1016/j.neulet.2009.01.040 · Cited by 20
A Cancer-Selective Zinc Ionophore Inspired by the Natural Product Naamidine A
Vaden, R. M., Guillen, K. P., Salvant, J. M., Santiago, C. B., Gibbons, J. B., Pathi, S. S., Arunachalam, S., Sigman, M. S., Looper, R., & Welm, B. E. (2018) · ACS Chemical Biology · doi:10.1021/acschembio.8b00977 · Cited by 20
Greer, J. B., Schmale, M. C., & Fieber, L. A. (2018) · BMC Genomics · doi:10.1186/s12864-018-4909-1 · Cited by 21
Clioquinol inhibits NGF-induced Trk autophosphorylation and neurite outgrowth in PC12 cells
Asakura, K., Ueda, A., Kawamura, N., Ueda, M., Mihara, T., & Mutoh, T. (2009) · Brain Research · doi:10.1016/j.brainres.2009.09.011 · Cited by 19
Copper homeostasis and cuproptosis: implications for neurodegenerative diseases
Tao, F., Lin, M., Meng, X., Huang, L., Zhuo, B., Jiang, S., Deng, S., Meng, Z., & Shi, J. (2025) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2025.1688554 · Cited by 30
Crystal Structures of Human FIH-1 in Complex with Quinol Family Inhibitors
Moon, H., Han, S., Park, H., & Choe, J. (2010) · Molecules and Cells · doi:10.1007/s10059-010-0058-3 · Cited by 20
“Recent findings have shown that CQ, functioning as a metal chelator, can be used to treat neurodegenerative diseases like Alzheimer’s and Huntington’s with controlled dosing and vitamin supplementation ( Nguyen et al., 2005; Raman et al., 2005; Ritchie et al., 2003).”
BackgroundStachowski, E. K., & Schwarcz, R. M. (2011) · Journal of Neural Transmission · doi:10.1007/s00702-011-0694-6 · Cited by 20
“…seen in animal models of Parkinson’s disease, Alzheimer’s disease and HD, i.e., disorders which have been linked to excitotoxic mechanisms and, specifically, to excess QUIN (Zecca et al. 2004; Nguyen et al. 2005; Németh et al. 2006; Chen and Guillemin 2009; Schwarcz et al. 2010; Li et al. 2011).”
Solution Chemistry of Copper(II) Binding to Substituted 8‑Hydroxyquinolines
Summers, K. L., Pushie, M. J., Sopasis, G. J., James, A. K., Dolgova, N. V., Sokaras, D., Kröll, T., Harris, H. H., Pickering, I. J., & George, G. N. (2020) · Inorganic Chemistry · doi:10.1021/acs.inorgchem.0c01356 · Cited by 20
Latosińska, J. N., Latosińska, M., Tomczak, M. A., Seliger, J., & Žagar, V. (2010) · Journal of Molecular Modeling · doi:10.1007/s00894-010-0876-4 · Cited by 17
On tautomerism and substituent effect in 8-hydroxyquinoline-derived medicine molecules
Karpińska, G., Mazurek, A. P., & Dobrowolski, J. C. (2010) · Journal of Molecular Structure THEOCHEM · doi:10.1016/j.theochem.2010.09.006 · Cited by 17
Neonatal Iron Supplementation Induces Striatal Atrophy in Female YAC128 Huntington’s Disease Mice
Berggren, K. L., Lu, Z., Fox, J. A., Dudenhoeffer, M., Agrawal, S., & Fox, J. H. (2016) · Journal of Huntington s Disease · doi:10.3233/jhd-150182 · Cited by 17
“While the extent to which iron homeostatic dysregulation may contribute to HD progression is unclear there is evidence to support protective effects of both weak and strong iron chelators in mouse HD [4, 12].”
Chen, Y., & Guillemi, G. (2012) · InTech eBooks · doi:10.5772/32332 · Cited by 16
Mutual Stimulation of Beta-Amyloid Fibrillogenesis by Clioquinol and Divalent Metals
Bolognin, S., Zatta, P. F., Drago, D., Parnigotto, P. P., Ricchelli, F., & Tognon, G. (2008) · NeuroMolecular Medicine · doi:10.1007/s12017-008-8046-x · Cited by 16
“…the size and number of Ab plaques, spontaneously generated in a mouse model of AD (Cherny et al. 2001), as well as in mouse models of Huntington’s (Cuajungco et al. 2000; Bush 2002; Nguyen et al. 2005) and Parkinson’s (Kaur et al. 2003) diseases, presumably by chelation of Ab-associated metal ions.”
BackgroundBrocardo, P. S., McGinnis, E., Christie, B. R., & Gil‐Mohapel, J. (2016) · Rejuvenation Research · doi:10.1089/rej.2015.1736 · Cited by 18
“Additionally, numerous antioxidant compounds have shown benefits when administered to different truncated transgenic mouse models of HD [18,34,49-59] and supplementation of symptomatic YAC128 full-length HD transgenic mice with the essential fatty acid ethyl-eicosapentaenoic acid (ethylR ej uv en at io n R es ea rc h”
Histone deacetylase inhibitor attenuates neurotoxicity of clioquinol in PC12 cells
Fukui, T., Asakura, K., Hikichi, C., Ishikawa, T., Murai, R., Hirota, S., Murate, K., Kizawa, M., Ueda, A., Ito, S., et al. (2015) · Toxicology · doi:10.1016/j.tox.2015.01.013 · Cited by 17
Huntington's and other polyglutamine diseases: many effects of single gene mutations
Luthi‐Carter, R. (2007) · Drug Discovery Today Disease Mechanisms · doi:10.1016/j.ddmec.2007.10.002 · Cited by 15
Characteristics, Pathophysiology and Clinical Management of Weight Loss in Huntington’s Disease
Aziz, N. A., & Roos, R. A. C. (2013) · Neurodegenerative Disease Management · doi:10.2217/nmt.13.22 · Cited by 17
Chen, P., Wang, Y., Tang, H., Zhou, C., Liu, Z., Gao, S., Wang, T., Yun, X., & Ji, S.-L. (2024) · Journal of Pharmaceutical Analysis · doi:10.1016/j.jpha.2024.101069 · Cited by 14
Calabrese, E. J., Bhatia, T. N., Calabrese, V., Dhawan, G., Giordano, J., Hanekamp, Y. N., Kapoor, R., Kozumbo, W. J., & Leak, R. K. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.104371 · Cited by 13
Wagner, L. A., Menalled, L., Goumeniouk, A. D., Brunner, D., & Leavitt, B. R. (2008) · Elsevier eBooks · doi:10.1016/b978-0-12-373861-5.00018-7 · Cited by 13
Lee, S. W., Park, H. J., Im, W., Kim, M., & Hong, S. (2018) · Animal Cells and Systems · doi:10.1080/19768354.2018.1473291 · Cited by 13
“week-old mice were suspended by the tail for 30 s, and the foot-clasping time was scored as follows: 3, >10 s; 2, 5–10 s; 1, 0–5 s; 0, 0 s (Nguyen et al. 2005).”
MethodExploring Old Drugs for the Treatment of Hematological Malignancies
Gan, F., Cao, B., Wu, D., Chen, Z., Hou, T., & Mao, X. (2011) · Current Medicinal Chemistry · doi:10.2174/092986711795328427 · Cited by 13
“Recently, clioquinol was revitalized as a novel agent in the treatment of Alzhemier’s Disease [63] and Huntington’s Disease [64].”
BackgroundiNKT Cell Activation Exacerbates the Development of Huntington’s Disease in R6/2 Transgenic Mice
Park, H. J., Lee, S. W., Im, W., Kim, M., Kaer, L. V., & Hong, S. (2019) · Mediators of Inflammation · doi:10.1155/2019/3540974 · Cited by 11
“For measuring clasping time, 4or 12-week-old mice were suspended by the tail for 30 s, and the foot-clasping time was measured as follows: 0, 0 s; 1, 0– 5 s; 2, 5–10 s; and 3, >10 s [14].”
MethodClioquinol kills astrocyte-derived KT-5 cells by the impairment of the autophagy–lysosome pathway
Mizutani, Y., Maeda, T., Murate, K., Ito, S., Watanabe, H., & Mutoh, T. (2020) · Archives of Toxicology · doi:10.1007/s00204-020-02943-8 · Cited by 12
Novel Mn(III) heterochelates: synthesis, thermal, spectroscopic, and coordination aspects
Modi, C. K., & Jani, D. H. (2010) · Journal of Thermal Analysis and Calorimetry · doi:10.1007/s10973-010-0890-x · Cited by 10
“Recent reports indicate that clioquinol also mitigates neuropathological symptoms of Huntington’s disease in a mouse model of this disorder [9]; clioquinol treatment decreased the accumulation of huntingtin aggregates, suggesting commonalities in the etiology of both neurological pathologies.”
BackgroundOliveri, V., Bentivegna, F., Caputo, L., Quintieri, L., Viale, M., Maric, I., Lentini, G., & Vecchio, G. (2018) · New Journal of Chemistry · doi:10.1039/c8nj00993g · Cited by 9
Berggren, K. L., Agrawal, S., Fox, J. A., Hildenbrand, J. R. V., Nelson, R., Bush, A. I., & Fox, J. H. (2017) · Journal of Huntington s Disease · doi:10.3233/jhd-170242 · Cited by 9
“Therapeutic studies in HD mouse models have demonstrated that compounds with ironchelating activity provide some protection (9, 17).”
Shanab, O., Mostafa, L., Abdeen, A., Atia, R. R. A., Nassar, A. Y., Youssef, M., Ibrahim, S. F., Maher, Z. M., Imbrea, F., Fericean, L. M., et al. (2023) · Ecotoxicology and Environmental Safety · doi:10.1016/j.ecoenv.2023.115841 · Cited by 11
Ligand Design to Target and Modulate Metal–Protein Interactions in Neurodegenerative Diseases
Beck, M. W., Pithadia, A. S., DeToma, A. S., Korshavn, K. J., & Lim, M. H. (2014) · Wiley eBooks · doi:10.1002/9781118697191.ch10 · Cited by 10
Conan, P., Léon, A., Gourdel, M., Rollet, C., Chaïr, L., Caroff, N., Goux, N. L., Jossic-Corcos, C. L., Sinane, M., Gentile, L., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23126769 · Cited by 6
“In the last years, CQ has also been proposed as a therapeutic drug for the treatment of Alzheimer’s [25] and Huntington’s diseases [26] based on its properties of metal homeostasis modulation [27,28].”
BackgroundTang, X., Jiao, L., Zheng, M., Yan, Y., Nie, Q., Wu, T., Wan, X., Zhang, G., Li, Y., Wu, S., et al. (2018) · Neuroscience · doi:10.1016/j.neuroscience.2018.01.002 · Cited by 8
“Actually, clioquinol is a meta-binding compound, which might show efficacy in combining Cu/Zn and discharges them out of the body (Nguyen et al., 2005).”
BackgroundNeurotoxicity of copper and copper nanoparticles
Joshi, A., Farber, K., & Scheiber, I. F. (2021) · Advances in neurotoxicology · doi:10.1016/bs.ant.2020.11.001 · Cited by 7
Schmitt, S. M., Deshmukh, R. R., & Dou, Q. P. (2014) · Resistance to targeted anti-cancer therapeutics · doi:10.1007/978-3-319-06752-0_1 · Cited by 8
The role of d-block metal ions in neurodegenerative diseases
Posadas, Y., López-Guerrero, V. E., Arcos‐López, T., Sayler, R. I., Sánchez‐López, C., Segovia, J., Perez‐Cruz, C., & Quintanar, L. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-823144-9.00115-1 · Cited by 7
New symptomatic therapies for Huntington disease
Deb, A., Frank, S., & Testa, C. M. (2017) · Handbook of clinical neurology · doi:10.1016/b978-0-12-801893-4.00017-1 · Cited by 7
“In early studies, PBT2 reduced aggregated huntingtin in the R6/2 mouse model (Nguyen et al., 2005), decreased toxic cellular effects in the Caenorhabditis elegans model (Cherny et al., 2012), and improved cognition in the Alzheimer disease mouse model (Adlard et al., 2008).”
BackgroundCopper in Brain and Neurodegeneration
Liddell, J. R., Bush, A. I., & White, A. R. (2004) · Wiley eBooks · doi:10.1002/9781119951438.eibc2143 · Cited by 6
Iron-Calcium Crosstalk in Neurodegenerative Diseases
Kadian, M., Sharma, G., & Kumar, A. (2022) · Nutritional neurosciences · doi:10.1007/978-981-19-7327-7_6 · Cited by 5
Alghamdi, S. A., Kabrah, A. M., Khidir, E. B. A., Al-Moraya, I. S., & Asif, M. (2023) · Mini-Reviews in Organic Chemistry · doi:10.2174/1570193x20666230711170721 · Cited by 7
Therapeutic Strategies in Huntington's Disease
Kanazawa, I. (2006) · Journal of Clinical Neurology · doi:10.3988/jcn.2006.2.4.213 · Cited by 7
Investigational drugs for the management of Huntington’s disease: are we there yet?
Kulkarni, P., & Saxena, U. (2014) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2014.934807 · Cited by 4
“An evidence for the detrimental role of metal ions was demonstrated in studies which showed that clioquinol, a metal chelator improves cognitive functions as well as downregulates expression of mHtt [48].”
BackgroundAli, M. G. H., Wahba, H. M., Igelmann, S., Cyr, N., Ferbeyre, G., & Omichinski, J. G. (2024) · Autophagy · doi:10.1080/15548627.2024.2353443 · Cited by 3
“…material 1), ULK1 (unc-51 like autophagy activating kinase 1), GABRG2/γ2-GABAAR (gamma-aminobutyric acid type A receptor subunit gamma2), WDFY3 and RETREG1/FAM134B (reticulophagy regulator 1) preferentially bind to the GABARAP subfamily in comparison to the LC3 subfamily [9,10,23,33–38].”
Bu, F., Guan, R., Wang, W., Liu, Z., Yin, S., Zhao, Y., & Chai, J. (2022) · Medicine · doi:10.1097/md.0000000000032100 · Cited by 4
“In ND, chloroquinoline promoted degradation of Aβ oligomers and inhibited accumulation to restore endocytosis and ameliorate Aβ toxicity and improve AD symptoms[120]; improved motor and non-motor deficits in a monkey model of MPTPinduced Parkinson’s disease via the AKT/mTOR pathway[121]; and improved behavioral and pa…”
BackgroundSelective Optimization of Side Activities: An Alternative and Promising Strategy for Lead Generation
Handler, N., Wolkerstorfer, A., & Buschmann, H. (2016) · Methods and principles in medicinal chemistry · doi:10.1002/9783527677047.ch09 · Cited by 3
Du, W., Wu, T., Fan, Y., & Zhao, M. (2025) · Neural Regeneration Research · doi:10.4103/nrr.nrr-d-25-00808 · Cited by 4
“In HD, CQ has been shown to reduce the expression of HTT and alleviate pathology in mouse models (Nguyen et al., 2005).”
Potential Therapeutic Strategies for Neurodegenerative Diseases
Farooqui, A. A. (2010) · Springer eBooks · doi:10.1007/978-1-4419-6652-0_9 · Cited by 2
Manganese and Huntington Disease
Tidball, A. M., Bichell, T. J., & Bowman, A. B. (2014) · Royal Society of Chemistry eBooks · doi:10.1039/9781782622383-00540 · Cited by 2
Metal Biology Associated with Huntington’s Disease
Bichell, T. J., Halbesma, T. C., Tipps, K. G., & Bowman, A. B. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-804562-6.00013-0 · Cited by 4
Role of Metals in Alzheimer Disease
Roberts, B. R., & Bush, A. I. (2010) · Wiley eBooks · doi:10.1002/9780470572702.ch24 · Cited by 2
Hope for Huntington's from an old antibiotic
Ashraf, H. (2005) · Drug Discovery Today · doi:10.1016/s1359-6446(05)03685-8 · Cited by 2
Castellano, S., Tosco, A., Milite, C., Viviano, M., Marzo, T., Taliani, S., & Sbardella, G. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6c00884 · Cited by 2
Hypoxia-Inducible Factor: Pattern of the Effects and Their Dualism
Maistrenko, A., Kopach, O., & Skibo, G. G. (2015) · Neurophysiology · doi:10.1007/s11062-015-9530-1 · Cited by 1
Copper metabolism and copper-mediated alterations in the metabolism of cultured astrocytes
Scheiber, I. F. (2012) · State and University Library Bremen · Cited by 1
Therapeutics of Alzheimer’s Disease Based on Metal Bioavailability
Bush, A. I., & Mok, S. S. (2009) · Oxidative stress and disease · doi:10.1201/9781420073522.ch9 · Cited by 1
Wehbe, M. (2017) · cIRcle (University of British Columbia) · doi:10.14288/1.0357144 · Cited by 2
“As such, CQ and later, PBT2, a second generation 8-HQ analogue, have been used to treat AD and HD [136-138].”
BackgroundTeil, M., Doudnikoff, É., Thiolat, M.-L., Bohic, S., Bézard, E., & Dehay, B. (2022) · Research Square · doi:10.21203/rs.3.rs-1396590/v1 · Cited by 1
In Silico Design of Preventive Drugs for Alzheimer’s Disease
Yadav, A., & Sonker, M. (2011) · InTech eBooks · doi:10.5772/16681
β-cell dysfunction in Huntington's disease
Bacos, K. (2009) · Lund University Publications (Lund University)
Neuroprotection in Huntington’s Disease
Jain, K. K. (2011) · Humana Press eBooks · doi:10.1007/978-1-61779-049-2_9
Chen, Z., Cao, Q., Qin, Q., Qin, J.-L., & Liang, H. (2017) · Scientia Sinica Chimica · doi:10.1360/n032016-00152
Electroanalysis of α-Synuclein Aggregation Related to Parkinson's Disease
Chan, T. (2011) · TSpace (University of Toronto)
Takeshima, H. (2010) · Elsevier eBooks · doi:10.1016/b978-0-12-374105-9.00258-6
Chaudhary, R. K., Patel, K. A., & Roy, I. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-809813-4.00010-7 · Cited by 1
Teil, M., Doudnikoff, É., Thiolat, M.-L., Bohic, S., Bézard, E., & Dehay, B. (2022) · Research Square · doi:10.21203/rs.3.rs-1396590/v2
Drug discovery in Alzheimer’s disease using metal chelators: Warning toward their usage
Mutoh, T. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-89906-2.00005-8
The Development of Metal‐Based Antioxidants as Anticancer Agents
Nilewar, S. S., Afroz, T., Dunn, S., Bosque, N. D., & Green, K. N. (2023) · Wiley eBooks · doi:10.1002/9781119951438.eibc2856 · Cited by 1
The SOSA Approach to Drug Discovery
Handler, N., Pozník, M., & Buschmann, H. (2024) · Wiley eBooks · doi:10.1002/9781394182862.ch21
Exploring and Targeting the Connection of Iron and Copper Homeostasis to Neurodegenerative Diseases
Liu, X., Jia, L., Wu, K., Chen, M., Sun, J., Yang, C., Xu, C., Sun, J., Wang, J., & Dai, L. (2026) · MedComm · doi:10.1002/mco2.70766
Milardi, D., Han, J., Lee, H. J., Ding, F., Miller, Y., Faller, P., Bush, A. I., Crouch, P. J., Finkelstein, D. I., Double, K. L., et al. (2026) · Chemical Reviews · doi:10.1021/acs.chemrev.5c00420 · Cited by 1
Dumała, S., Jędrzejewska, A., Kwaśniak-Butowska, M., Sousa, P. A. D., & Tomczyk, M. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1984341
Metadata
- Authors
- Nguyen, T., Hamby, A., & Massa, S. M.
- Affiliations
- San Francisco VA Medical Center (US)
- ORCID
- Massa, Stephen M.
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2005-08-08
- Volume
- 102
- Issue
- 33
- Pages
- 11840-11845
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC1187967
- OpenAlex
- W2009252276
- Cited by
- 194
- References
- 54
- Citations by year
- 2026: 3 · 2025: 3 · 2024: 6 · 2023: 4 · 2022: 8 · 2021: 4 · 2020: 7 · 2019: 3 · 2018: 10 · 2017: 8 · 2016: 8 · 2015: 13 · 2014: 14 · 2013: 10 · 2012: 14
- FWCI
- 4.35
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Genetic Neurodegenerative Diseases
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Prion Diseases and Protein Misfolding
- Keywords
- clioquinol, Huntington's disease, mutant huntingtin, polyglutamine expansion, metal ions, huntingtin aggregates, striatal atrophy, R6/2 transgenic mice, neuroprotection, lifespan extension
- MeSH terms
- Huntingtin Protein, Animals, Behavior, Animal, Blood Glucose, Body Weight, Cell Line, Disease Models, Animal, Female, Humans, Huntington Disease, Insulin, Clioquinol, Male, Mice, Transgenic, Mutation, Nerve Tissue Proteins, Nuclear Proteins, Pancreas, Peptides, RNA, Messenger, Down-Regulation, Survival Rate, Cell Death, Mice, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.